Abstract
Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32% (95% confidence interval 24-40%); 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%. The overall survival was 6 months; 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature, the complete response rates are quite similar and the long-term disease-free survival of these combinations may be similar to that of dacarbazine alone.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ahmann D. L., Creagan E. T., Hahn R. G., Edmonson J. H., Bisel H. F., Schaid D. J. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer. 1989 Jan 15;63(2):224–227. doi: 10.1002/1097-0142(19890115)63:2<224::aid-cncr2820630203>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
- Balch C. M., Soong S. J., Murad T. M., Smith J. W., Maddox W. A., Durant J. R. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983 Feb;1(2):126–134. doi: 10.1200/JCO.1983.1.2.126. [DOI] [PubMed] [Google Scholar]
- Hill G. J., 2nd, Krementz E. T., Hill H. Z. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984 Mar 15;53(6):1299–1305. doi: 10.1002/1097-0142(19840315)53:6<1299::aid-cncr2820530613>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
- Luger S. M., Kirkwood J. M., Ernstoff M. S., Vlock D. R. High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst. 1990 Dec 19;82(24):1934–1937. doi: 10.1093/jnci/82.24.1934. [DOI] [PubMed] [Google Scholar]
- Mulder N. H., Sleijfer D. T., Smit J. M., De Vries E. G., Willemse P. H., Koops H. S. Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma. Eur J Cancer Clin Oncol. 1986 Jul;22(7):879–881. doi: 10.1016/0277-5379(86)90377-9. [DOI] [PubMed] [Google Scholar]
- Mulder N. H., Sleijfer D. T., de Vries E. G., Schraffordt Koops H., Samson M. J., Willemse P. H. Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol. 1989;115(1):93–95. doi: 10.1007/BF00391607. [DOI] [PubMed] [Google Scholar]
- Mulder N. H., Willemse P. H., Schraffordt Koops H., de Vries E. G., Sleijfer D. T. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma. Br J Cancer. 1990 Dec;62(6):1006–1007. doi: 10.1038/bjc.1990.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mulder N. H., de Vries E. G., Sleijfer D. T., Schraffordt Koops H., Willemse P. H. Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma. Br J Cancer. 1992 Feb;65(2):303–304. doi: 10.1038/bjc.1992.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Presant C. A., Bartolucci A. A. Prognostic factors in metastatic malignant melanoma: The Southeastern Cancer Study Group Experience. Cancer. 1982 May 15;49(10):2192–2196. doi: 10.1002/1097-0142(19820515)49:10<2192::aid-cncr2820491035>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
- Pyrhönen S., Hahka-Kemppinen M., Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol. 1992 Dec;10(12):1919–1926. doi: 10.1200/JCO.1992.10.12.1919. [DOI] [PubMed] [Google Scholar]